Spring is in the air, and the annual NCAA March Madness college basketball tournament has once again captivated the nation. Of course, that also means Cinderella stories like Wichita State have busted the brackets of would-be basketball prognosticators.
Here at The Motley Fool, we decided to stick with what we know, trading our basketball picks in for stock picks. We formed our own bracket filled with the top Big Pharma and Big Biotech stocks in a winner-take-all tournament as determined by the collective intelligence of our CAPS community.
This Elite Eight matchup is a heavyweight bout between AstraZeneca and AbbVie. Watch and find out which stock gets eliminated and which will advance to the next round.
In the pharma business, great success comes with a caveat. AbbVie is a perfect example, as investors in the new company are left wondering what the future holds once the company's golden goose, Humira, is cooked. The Fool's brand-new premium report on the company answers the high-profile questions that AbbVie investors are asking. Simply click here now to claim your copy today.